European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.61% to 1,444.24 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by Sequans Communications (SQNS) and financial services company ING Groep (ING), which rose 6.8% and 4.2% respectively. They were followed by financial services company Banco Santander (SAN) and biopharmaceutical company Genfit (GNFT), which were up 2.2% each.
The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and pharmaceutical company Novo Nordisk (NVO), which fell 3.7% and 2.1% respectively. They were followed by biotech firm BioNTech (BNTX) and biopharmaceutical company Cellectis (CLLS), which lost 1.9% and 1.3% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies TC Biopharm (TCBP) and Akari Therapeutics (AKTX), which advanced 16.7% and 8.8% respectively. They were followed by communications company WPP (WPP) and biopharmaceutical company Verona Pharma (VRNA), which increased 3.5% and 1.7% respectively.
The decliners from the UK and Ireland were led by educational publisher Pearson (PSO) and hospitality company InterContinental Hotels Group (IHG), which dropped 3.6% and 3.1% respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and cruise line operator Carnival (CUK), which were down 5% and 2.9% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.